FDA approves Leqembi Iqlik® (lecanemab-irmb) subcutaneous injection as a starting dose for early Alzheimer's disease
BLA FilingapprovedLeqembi IqlikPositive
AI Analysis
Summary
The FDA approved Eisai's supplemental Biologics License Application for Leqembi Iqlik (lecanemab-irmb) subcutaneous injection as a once-weekly starting dose for early Alzheimer's disease, expanding treatment options for patients. BioArctic AB is a partner in the development of this formulation.
Outcome Details
FDA approved supplemental Biologics License Application (sBLA) for once weekly lecanemab-irmb subcutaneous injection as a starting dose for early Alzheimer's disease
Importance:9/10
Sentiment:
0.90
FDA approvalAlzheimer's diseasesubcutaneous injectionsBLALeqembilecanemab
Read the original article
Published by PR Newswire Pharma on July 14, 2026 2:42 AM